FindTrial
Sign In

CVM-1118

DRUG3 trials

Sponsors

TaiRx, Inc.

Conditions

Advanced CancerGastro-enteropancreatic Neuroendocrine TumorHepatocellular CarcinomaLung Neuroendocrine NeoplasmNeuroendocrine CarcinomaNeuroendocrine TumorsPancreatic Neuroendocrine Tumor

Phase 2

CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TerminatedNCT03582618
TaiRx, Inc.Advanced Cancer, Hepatocellular Carcinoma
Start: 2018-07-12End: 2022-12-30Updated: 2023-01-10
Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors
Active, not recruitingNCT03600233
TaiRx, Inc.Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma +2
Start: 2018-12-15End: 2026-03-31Updated: 2025-12-23
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
RecruitingNCT05257590
TaiRx, Inc.Advanced Cancer, Hepatocellular Carcinoma
Start: 2022-05-23End: 2026-03-31Target: 95Updated: 2025-12-17

Related Papers

CVM-1118: An oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.
Journal of Clinical Oncology2024-08-101 citations
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in combination with nivolumab in patients with unresectable advanced hepatocellular carcinoma (HCC)—A phase IIa study.
Journal of Clinical Oncology2024-06-011 citations
CVM-1118: A potent oral anti-vasculogenic mimicry (VM) agent in patients with advanced neuroendocrine tumors (NETs)—A phase IIa study.
Journal of Clinical Oncology2023-06-013 citations